Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unveiling the molecular profile of adenosquamous gallbladder carcinoma: characterization of a Caucasian cohort.

Histopathology·2026
Same author

MTAP loss in gallbladder carcinoma: frequency, heterogeneity and expression in precursor lesions.

Journal of clinical pathology·2026
Same author

DNA Methylation in Gastric Cancer and Preneoplastic Lesions: Emerging Insights and Future Directions.

Cancers·2026
Same author

Biological variation outweighs pre-analytical factors in coagulation reference intervals: a multicenter big data study.

Clinica chimica acta; international journal of clinical chemistry·2026
Same author

Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy.

Gut·2025
Same author

Rectus femoris ultrasound identifies sarcopenia and predicts poor outcomes in patients with acute decompensation of cirrhosis.

JHEP reports : innovation in hepatology·2025
Same journal

Quantitative Abdominal Aortic Calcification Morphology Is Associated With Lumen Geometry.

Journal of vascular research·2026
Same journal

Systemic Inflammatory Indices Predict Survival and Limb Outcomes after Revascularization for Chronic Limb-Threatening Ischemia.

Journal of vascular research·2026
Same journal

Exploring Sexual Dimorphism and Genetic Variability in Cutaneous Microhemodynamics in BALB/c, C57BL/6J, and KM Mice.

Journal of vascular research·2026
Same journal

Effects of exercise mode and intensity on retinal microvascular structure and function in heart failure patients with preserved ejection fraction: a pilot exercise intervention trial.

Journal of vascular research·2026
Same journal

Hemodynamic stress as a cause of the high prevalence of arterial disease in women.

Journal of vascular research·2026
Same journal

Stage-Associated MicroRNA Expression Patterns in Human Great Saphenous Veins Across Chronic Venous Disease Severity.

Journal of vascular research·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

INHIBITION OF H₂S PRODUCTION REDUCES PORTAL PRESSURE AND ATTENUATES LIVER FIBROSIS IN BILE DUCT-LIGATED RATS.

Raffaele Buono, Marika Crescenzi, Alessandra Brocca

    Journal of Vascular Research
    |May 18, 2026
    PubMed
    Summary
    This summary is machine-generated.

    Inhibiting hydrogen sulfide (H2S) synthesis in rats with liver disease reduced portal pressure and liver fibrosis. This suggests H2S inhibition could be a therapeutic strategy for portal hypertension.

    More Related Videos

    Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
    09:37

    Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

    Published on: August 1, 2018

    Isolation of Rat Portal Fibroblasts by In situ Liver Perfusion
    07:39

    Isolation of Rat Portal Fibroblasts by In situ Liver Perfusion

    Published on: June 29, 2012

    Related Experiment Videos

    Last Updated: May 20, 2026

    Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
    08:56

    Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

    Published on: February 10, 2015

    Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
    09:37

    Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

    Published on: August 1, 2018

    Isolation of Rat Portal Fibroblasts by In situ Liver Perfusion
    07:39

    Isolation of Rat Portal Fibroblasts by In situ Liver Perfusion

    Published on: June 29, 2012

    Area of Science:

    • Hepatology
    • Gastroenterology
    • Pharmacology

    Background:

    • Hydrogen sulfide (H2S) is a signaling molecule impacting liver inflammation and fibrosis.
    • Bile duct ligation (BDL) in rats is a model for liver disease and portal hypertension.

    Purpose of the Study:

    • To investigate the therapeutic potential of inhibiting H2S synthesis in BDL-induced liver disease.
    • To assess the effects of propargylglycine (PAG), an H2S synthesis inhibitor, on liver fibrosis and portal hypertension.

    Main Methods:

    • Rats underwent BDL and were treated with PAG or vehicle.
    • Portal pressure, systemic pressure, and mesenteric artery responses were measured.
    • Liver fibrosis markers (IL-6, TGFβ, collagen I) and liver enzymes were analyzed.

    Main Results:

    • PAG treatment significantly reduced portal pressure in BDL rats.
    • PAG attenuated hepatic fibrosis, architectural distortion, and lowered liver enzymes.
    • No significant changes in systemic pressure or mesenteric artery reactivity to acetylcholine or H2S were observed.

    Conclusions:

    • Inhibition of H2S synthesis decreases portal pressure and liver fibrosis in a rat model.
    • Targeting H2S may offer a novel therapeutic approach for managing portal hypertension.
    • Modulation of intrahepatic resistance is a potential mechanism for H2S inhibition's effects.